HOOKIPA Pharma Files 8-K
Ticker: HOOK · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1760542
| Field | Detail |
|---|---|
| Company | Hookipa Pharma Inc. (HOOK) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, procedural
TL;DR
HOOKIPA Pharma filed a standard 8-K, no major news.
AI Summary
HOOKIPA Pharma Inc. filed an 8-K on January 10, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events, financial figures, or material agreements, but rather serves as a procedural update.
Why It Matters
This 8-K filing indicates a routine update from HOOKIPA Pharma Inc. to the SEC, without disclosing new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine procedural update and does not contain any new material information that would inherently increase risk.
Key Players & Entities
- HOOKIPA Pharma Inc. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 350 Fifth Avenue, 72nd Floor, Suite 7240 (address) — Principal Executive Offices
- New York (location) — City of Principal Executive Offices
- 10118 (zip_code) — Zip Code of Principal Executive Offices
- +43 1 890 63 60 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by HOOKIPA Pharma Inc.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of January 10, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 10, 2025.
In which state was HOOKIPA Pharma Inc. incorporated?
HOOKIPA Pharma Inc. was incorporated in Delaware.
What is the principal executive office address for HOOKIPA Pharma Inc.?
The principal executive office address is 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY 10118.
Does this filing disclose any new material financial information or business developments?
No, this filing does not appear to disclose any new material financial information or specific business developments beyond procedural reporting.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-10 16:00:19
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq
Filing Documents
- tm252889d1_8k.htm (8-K) — 28KB
- tm252889d1_ex99-1.htm (EX-99.1) — 34KB
- 0001104659-25-002517.txt ( ) — 241KB
- hook-20250110.xsd (EX-101.SCH) — 3KB
- hook-20250110_lab.xml (EX-101.LAB) — 33KB
- hook-20250110_pre.xml (EX-101.PRE) — 22KB
- tm252889d1_8k_htm.xml (XML) — 4KB
01 Other Information
Item 8.01 Other Information. As previously reported, on January 2, 2025, HOOKIPA Pharma Inc. (the "Company") and Poolbeg Pharma plc ("Poolbeg") released an announcement pursuant to Rule 2.4 of the U.K. City Code on Takeovers and Mergers that the Company and Poolbeg have entered into non-binding discussions for the potential acquisition by the Company of the entire issued share capital of Poolbeg (the "2.4 Announcement"). On January 10, 2025, the Company and Poolbeg released an update to the 2.4 Announcement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Update to Announcement pursuant to Rule 2.4 of the U.K. City Code on Takeovers and Mergers, dated January 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2025 HOOKIPA Pharma Inc. By: /s/ Terry Coelho Name: Terry Coelho Title: Executive Vice President and Chief Financial Officer